Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

S. Korea Doubles Number Of Asbestos-Tainted Drugs Allowed On Sale

This article was originally published in PharmAsia News

Executive Summary

South Korea's FDA has decided to add 11 more drugs believed tainted with asbestos to remain for sale through May 8. The decision increases the number of asbestos-tainted medicines allowed to remain on the market to 22 out of the 1,122 identified by the agency as possibly contaminated with the carcinogen (PharmAsia News, April 10, 2009). The agency eased the restrictions for the 22 on grounds there were no suitable replacements for them. The other 1,100 drugs have been banned and removed from store shelves if they were made before April 3, when the agency issued a ban on the use of talc to remove asbestos. (Click here for more

Table

View full table

Tags:
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC071327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By